Advertisement
Canada markets close in 4 hours 32 minutes
  • S&P/TSX

    21,920.51
    +35.13 (+0.16%)
     
  • S&P 500

    5,097.86
    +49.44 (+0.98%)
     
  • DOW

    38,171.33
    +85.53 (+0.22%)
     
  • CAD/USD

    0.7306
    -0.0017 (-0.24%)
     
  • CRUDE OIL

    83.78
    +0.21 (+0.25%)
     
  • Bitcoin CAD

    86,878.68
    -229.58 (-0.26%)
     
  • CMC Crypto 200

    1,325.20
    -71.33 (-5.11%)
     
  • GOLD FUTURES

    2,345.80
    +3.30 (+0.14%)
     
  • RUSSELL 2000

    1,995.74
    +14.62 (+0.74%)
     
  • 10-Yr Bond

    4.6650
    -0.0410 (-0.87%)
     
  • NASDAQ

    15,921.21
    +309.46 (+1.98%)
     
  • VOLATILITY

    15.52
    +0.15 (+0.98%)
     
  • FTSE

    8,139.26
    +60.40 (+0.75%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6839
    +0.0018 (+0.26%)
     

Why BioNTech Was a Sickly Stock on Monday

BioNTech (NASDAQ: BNTX), the out-of-nowhere German biotech that shot to prominence with the coronavirus vaccine it developed with Pfizer (NYSE: PFE), wasn't having a great Monday. For its second quarter, BioNTech's revenue was just under 3.2 billion euros, or $3.3 billion, while its net profit stood at 1.67 billion euros. In that frame, BioNTech's top line was a bit over 5.3 billion euros, and it netted almost 2.79 billion euros in profit.